STOCK TITAN
  1. Home
  2. News
  3. TCRX

TScan Therapeutics, Inc. - $TCRX STOCK NEWS

Welcome to our dedicated page for TScan Therapeutics news (Ticker: $TCRX), a resource for investors and traders seeking the latest updates and insights on TScan Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TScan Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TScan Therapeutics's position in the market.

News
TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commercialization and Global Operations
Rhea-AI Summary
TScan Therapeutics, Inc. (Nasdaq: TCRX) appoints R. Keith Woods, a highly experienced leader in the biopharmaceutical sector, to its Board of Directors. With over 30 years of life science experience, Mr. Woods brings expertise in commercialization, sales, global operations, and business strategy. His appointment is expected to support the growth of TScan and advance its compelling pipeline of T cell receptor (TCR)-engineered T cell therapies for cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.59%
Tags
management
-
News
TScan Therapeutics to Host Virtual KOL Event to Discuss Results from Ongoing Phase 1 Trial of TSC-100 and TSC-101 Presented at the 65th ASH Annual Meeting and Exposition
Rhea-AI Summary
TScan Therapeutics, Inc. (Nasdaq: TCRX) will host a virtual KOL event to discuss highlights from its poster presentation at the 65th ASH Annual Meeting and Exposition. The event will focus on lead TCR-T cell therapy candidates, TSC-100 and TSC-101, designed to target HA-1 and HA-2, respectively, to treat residual disease and prevent relapse in patients with acute myeloid leukemia, acute lymphocytic leukemia, or myelodysplastic syndromes undergoing allogeneic haploidentical hematopoietic cell transplantation with reduced intensity conditioning.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.46%
Tags
conferences clinical trial
-
News
TScan Therapeutics Expands Manufacturing Leadership with the Appointment of Justin McCue, Ph.D., as Chief Technology Officer
Rhea-AI Summary
TScan Therapeutics, Inc. (Nasdaq: TCRX) appoints Justin McCue, Ph.D., as its Chief Technology Officer, bringing over 20 years of experience in biologics and cell therapy manufacturing. Dr. McCue's expertise will support the advancement of TScan's heme program and the launch of its multi-TCR-T solid tumor program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.56%
Tags
management
News
TScan Therapeutics Named Top Place to Work by The Boston Globe for Two Consecutive Years
Rhea-AI Summary
TScan Therapeutics, Inc. (Nasdaq: TCRX) has been named one of the Top Places to Work in Massachusetts in the 16th annual employee-based survey project from The Boston Globe. The company focuses on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for cancer treatment. The recognition highlights the company's positive work environment and employee satisfaction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.98%
Tags
none
-
News
TScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
TScan Therapeutics, Inc. (Nasdaq: TCRX) reported financial results and provided a corporate update for Q3 2023. The company will present initial data from a heme malignancies Phase 1 trial at the 65th ASH Annual Meeting. Recent FDA clearance of IND for TSC-203-A0201 targeting PRAME. Ended Q3 with $215.4 million in cash and marketable securities, funding operations into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.92%
Tags
earnings
-
News
TScan Therapeutics Presents Phase 1 Trial Design for Solid Tumor Program at the Society for Immunotherapy of Cancer 38th Annual Meeting
Rhea-AI Summary
TScan Therapeutics announces the presentation of six posters at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting. The company's solid tumor program aims to deliver multiplexed T cell receptor (TCR)-engineered T cell therapy for solid tumors. They have initiated a screening protocol to test for target expression and the presence of HLA genes in patients' tumors. TScan expects to enroll the first patient in their treatment protocol this year. They are also developing TCR-T cell therapies targeting novel melanoma-associated antigen C2 (MAGE-C2) and plan to file an IND for TSC-201-B0702 by the end of the year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.03%
Tags
clinical trial
News
TScan Therapeutics Announces Upcoming Presentation at the 65th American Society of Hematology Annual Meeting and Exposition
Rhea-AI Summary
TScan Therapeutics, Inc. announces the acceptance of an abstract for poster presentation at the ASH Annual Meeting. The company will host a virtual KOL event featuring Dr. Monzr M. Al Malki to discuss the data presented at ASH.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.73%
Tags
conferences
-
News
TScan Therapeutics Announces Upcoming Presentations at the 38th Society for Immunotherapy of Cancer Annual Meeting
Rhea-AI Summary
TScan Therapeutics accepted six abstracts at the SITC Annual Meeting, presenting TCR-T cell therapies for cancer treatment. The presentation materials will be available on the company's Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.11%
Tags
conferences
-
News
TScan Therapeutics to Participate in Upcoming Investor Conferences
Rhea-AI Summary
TScan Therapeutics, Inc. (Nasdaq: TCRX) to participate in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.07%
Tags
conferences
News
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-203-A0201 Targeting PRAME
Rhea-AI Summary
TScan Therapeutics receives FDA clearance for TCR-T cell therapy targeting PRAME in solid tumors, positive clinical trial progress reported
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.96%
Tags
clinical trial
Stock TCRX logo
TScan Therapeutics, Inc.

Nasdaq:TCRX

TCRX Rankings

#3067 Ranked by Market Cap
#745 Ranked by Stock Gains
N/A Ranked by Dividends

TCRX Stock Data

475.24M
21.10M
0.89%
83.08%
0.46%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
WALTHAM

About TCRX

harnessing novel t cell systems to extend the promise of immunotherapy